CLDN18.2
1 EU-approved indication of 1 drug needs a CLDN18.2 result, in 1 tumour type, most of them in gastric and GEJ adenocarcinoma.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Gastric and GEJ adenocarcinoma1 | ||||
Vyloy | Claudin (CLDN) 18.2 positive, HER2-negative | + fluoropyrimidine- and platinum-containing chemotherapy | 1L advanced | None |
CLDN18.2 by tumour
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Zolbetuximab (Vyloy)
Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive (see section 4.2).